"10.1371_journal.pone.0119852","plos one","2015-03-06T00:00:00Z","Nomi Werbeloff; Bruce P Dohrenwend; Rinat Yoffe; Jim van Os; Michael Davidson; Mark Weiser","Department of Psychiatry, Sheba Medical Center, Tel-Hashomer, Israel; Department of Psychiatry and Mailman School of Public Health, Columbia University, New York, New York, United States of America; New York State Psychiatric Institute, New York, New York, United States of America; Division of Mental Health Services, Ministry of Health, Jerusalem, Israel; Department of Psychiatry and Psychology, Maastricht University Medical Centre, Maastricht, The Netherlands; Department of Psychosis Studies, Kings College London, Kings Health Partners, London, United Kingdom","Conceived and designed the experiments: MW MD. Analyzed the data: MW NW JvO. Contributed reagents/materials/analysis tools: IL BPD ZH RY. Wrote the paper: MW NW JvO MD IL BPD.","Nomi Werbeloff, Bruce P. Dohrenwend, and Rinat Yoffe report no conflicts of interest in relation to the subject of this study. Jim van Os has received unrestricted investigator-led research grants or recompense for presenting his research from Eli Lilly, Bristol-Myers Squibb, Lundbeck, Organon, Janssen-Cilag, GlaxoSmithKline, AstraZeneca, Pfizer and Servier, companies that have an interest in the treatment of psychosis. Michael Davidson holds stocks in TGD and BiolineRx and has received research grant support and/or travel support and/or speaker fees and/or consultancy fees from JNJ, Pfizer, Lundbeck, Teva, BioLineRx, Eli Lilly, Sanofi-Aventis, Roche, GSK, Servier, Envivo, and Novartis. Mark Weiser has received research grant support and/or travel support and/or consultant fees and/or speaker fees from Eli Lilly, AstraZeneca, Janssen-Cilag, Pfizer, Lundbeck, Teva, BioLineRx, Sanofi-Aventis and Roche. The authors confirm that their declaration of competing interests does not alter their adherence to PLOS ONE policies on sharing data and materials.","2015","03","Nomi Werbeloff","NW",6,TRUE,NA,NA,NA,NA,NA,NA,NA,NA,NA
